Table 2

Summary of NADC and ADC reported in the D:A:D study from 2004-2010
n (% of total events)
Number of NADC events 880 (100.0)
Lung cancer 140 (15.9)
Hodgkin’s lymphoma 112 (12.7)
Anal cancer 79 (9.0)
Head and neck cancers 71 (8.1)
Liver cancer 59 (6.7)
Prostate 57 (6.5)
Breast cancer 43 (4.9)
Malignant melanoma 31 (3.5)
Colon cancer 26 (3.0)
Bladder cancer 21 (2.4)
Rectal 20 (2.3)
Gynecological cancers* 14 (1.6)
Stomach 13 (1.5)
Penile cancer 12 (1.4)
Kidney cancers 12 (1.4)
Acute myeloid leukemia 11 (1.3)
Metastasis of adenocarcinoma 9 (1.0)
Testicular 9 (1.0)
Lip cancer 6 (0.7)
Uterus 5 (0.6)
Brain cancer 5 (0.6)
Multiple myeloma 5 (0.6)
Metastasis of other cancer type 5 (0.6)
Metastasis of squamous cell carcinoma 5 (0.6)
Metastasis unspecified 4 (0.5)
Chronic lymphatic leukemia 2 (0.2)
Chronic myeloid leukemia 2 (0.2)
Connective tissue cancer 2 (0.2)
Bone cancer 1 (0.1)
Acute lymphatic leukemia 1 (0.1)
Leukemia unspecified 1 (0.1)
Type unknown 8 (0.9)
Unknown primary cancer 7 (0.8)
Other** 82 (9.3)
Number of ADC events 621 (100.0)
Kaposi’s sarcoma 331 (53.3)
Non-Hodgkin’s lymphoma 251 (40.4)
Cervical carcinoma 46 (7.4)

*Other than uterus and cervical cancer.

**Esophageal cancer, pancreas cancer, gall bladder cancer.

Worm et al.

Worm et al. BMC Infectious Diseases 2013 13:471   doi:10.1186/1471-2334-13-471

Open Data